Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Laboratorios Sophia S.A de C.V. clinical trials
The registry lists 45 studies whose lead sponsor is Laboratorios Sophia S.A de C.V.. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 14, 2026.
Keep track of what changes. Save the Laboratorios Sophia S.A de C.V. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Laboratorios Sophia S.A de C.V..
- Laboratorios Sophia S.A de C.V.45 studiesSame company
Something wrong?
Focus areas
Conditions Laboratorios Sophia S.A de C.V. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 45 of 45.
- Safety and Immunogenicity of PRO-169 in Patients With Diabetic Macular EdemaNot yet recruitingNCT07429474Phase 1
- PRO-232 in Patients Subjected to Cataract SurgeryRecruitingNCT07305987Phase 3
- Study to Evaluate the Efficacy of Alleance® (Atropine Sulfate 0.01%) as a Treatment to Delay Myopia and Axial Ocular Elongation in Children.RecruitingNCT06389110Phase 3
- Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®Not yet recruitingNCT06375343Phase 1
- Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.Not yet recruitingNCT06379685Phase 1
- Clinical Study to Evaluate PRO-169 for Diabetic Macular EdemaCompletedNCT05217680Phase 3
- Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.TerminatedNCT04702789Phase 4
- Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo.CompletedNCT06352541Phase 1
- Evaluation of Manzanilla® and Meticel Ofteno® 0.5% for Providing a Relief Sensation to the EyesCompletedNCT06859476Phase 4
- Study to Evaluate the Efficacy of Lagricel® Ofteno PF Compared to Thealoz® Duo After Photorefractive KeratectomyCompletedNCT04704518Phase 4
- Phase II Clinical Study to Evaluate the Efficacy of Multidose Lagricel® Ofteno Ophthalmic Solution as Treatment for Dry Eye Disease.CompletedNCT04704531Phase 2
- Study to Compare the Efficacy of the Ophthalmic Solution Humylub Ofteno® PF With Hyabak® and Lagricel Ofteno® PF as Treatment for Dry Eye.CompletedNCT04702776Phase 4
- Phase I Clinical Trial to Evaluate the Safety and Tolerability of Ophtalmic Solution PRO-201CompletedNCT05470881Phase 1
- Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime GelCompletedNCT03697876Phase 1
- Study to Evaluate the Safety of the Viscoelastic Substance PRO-149, Compared to Healon® EndoCoat.CompletedNCT04702802Not applicable
- Safety and Tolerability of PRO-185CompletedNCT05470868Phase 1
- Clinical Trial to Compare the Safety and Efficacy of Nanodrop®CompletedNCT04111965Phase 1/2
- Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+CompletedNCT04693429Phase 1
- Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy SubjectsCompletedNCT06363292Phase 1
- PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)TerminatedNCT03193333Phase 3
- Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel® Ofteno PFCompletedNCT06370585Phase 1
- Study of Non-inferiority Between Manzanilla Sophia® and Meticel Ofteno® 0.5% for Providing a Soothing Sensation to the Eyes.WithdrawnNCT06373653Phase 4
- Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular HypertensionTerminatedNCT02801617Phase 3
- Safety and Tolerability Evaluation of PRO-230 Ophthalmic SolutionWithdrawnNCT05481489Phase 1
- Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%.TerminatedNCT03696342Phase 3
- Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic SolutionCompletedNCT04081610Phase 1
- Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno®CompletedNCT03966365Phase 1
- Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan®CompletedNCT03965052Phase 1
- Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)CompletedNCT03257813Phase 3
- Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After PhacoemulsificationCompletedNCT03693989Phase 3
- Efficacy and Safety of PRO-155 on Inflammation of the Conjunctival Surface in Subjects With Grade I-III Pterygium vs Placebo.CompletedNCT03521791Phase 4
- Efficacy and Safety of the Ophthalmic Solution PRO-087 Versus Systane ® Ultra and Ultra Preservative Free (087LATAMFIV)CompletedNCT03223909Phase 4
- Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy SubjectsCompletedNCT03519516Phase 1
- Safety and Tolerability of the Ophthalmic Solution PRO-156 in Ophthalmologically Healthy Volunteers.CompletedNCT01871077Phase 1
- Safety and Tolerability of PRO-155 Ophthalmic Solution 0.09% in Healthy Volunteers.CompletedNCT01535443Phase 1
- Clinical Study of A Fixed Combination of Timolol-Brimonidine-DorzolamideCompletedNCT01062971Phase 2
- Safety and Tolerability of the Ophthalmic Gel PRO-167 Versus Corneregel® on Healthy Subjects.CompletedNCT03520348Phase 1
- Safety and Tolerability of PRO-087 Versus Xyel Ofteno® and Systane Ultra®, on the Ocular Surface of Healthy SubjectsCompletedNCT03524157Phase 1
- Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)CompletedNCT02980523Phase 2
- Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye SyndromeCompletedNCT01541891Phase 2
- Efficacy and Safety of PRO-155 Versus Nevanac in Post PhacoemulsificationCompletedNCT01657266Phase 2
- Safety and Tolerability of PRO-143 Ophthalmic Solution in Healthy Volunteers.WithdrawnNCT03698045Phase 1
- Clinical Efficacy of PRO-118 Compared With Olopatadine Hydrochloride Ophthalmic Solution in Allergic ConjunctivitisWithdrawnNCT01657240Phase 3
- Efficacy and Safety of PRO-118 Ophthalmic Solution in Allergic ConjunctivitisWithdrawnNCT01541904Phase 2
- Efficacy and Safety of PRO-148 Versus Systane®, in Patients With Mild to Moderate Dry EyeCompletedNCT01657253Phase 3